Last reviewed · How we verify
Corlanor (IVABRADINE)
Corlanor (generic name: IVABRADINE) is a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker Small molecule drug developed by Amgen. It is currently FDA-approved (first approved 2015) for Angina pectoris, Chronic heart failure.
Corlanor (Ivabradine) is a small molecule hyperpolarization-activated cyclic nucleotide-gated channel blocker developed by Amgen Inc. It targets the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 to treat angina pectoris and chronic heart failure. Corlanor is a patented medication with no generic manufacturers available. Key safety considerations include bradycardia and worsening heart failure in certain patients. It was FDA-approved in 2015.
At a glance
| Generic name | IVABRADINE |
|---|---|
| Sponsor | Amgen |
| Drug class | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker |
| Target | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Angina pectoris
- Chronic heart failure
Common side effects
- Bradycardia
- Hypertension
- Atrial fibrillation
- Phosphenes
- Syncope
- Hypotension
- Torsade de pointes
- Ventricular fibrillation
- Ventricular tachycardia
- Angioedema
- Erythema
- Rash
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- Ivabradine for Heart Rate Control In Septic Shock (PHASE3)
- De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (PHASE4)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (PHASE2)
- Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC) (PHASE3)
- Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM) (NA)
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2,PHASE3)
- Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS) (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corlanor CI brief — competitive landscape report
- Corlanor updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Corlanor
What is Corlanor?
What is Corlanor used for?
Who makes Corlanor?
What is the generic name of Corlanor?
What drug class is Corlanor in?
When was Corlanor approved?
What development phase is Corlanor in?
What are the side effects of Corlanor?
What does Corlanor target?
Related
- Drug class: All Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker drugs
- Target: All drugs targeting Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Chronic heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing